Abbott's Architect HE4 (Human Epididymis Protein 4) assay, a new diagnostic test to monitor ovarian cancer, has received FDA clearance. It is an automated test available in the US, which uses a simple blood test to aid in monitoring for the recurrence or progression of ovarian cancer.
Abbott has collaborated with Fujirebio Diagnostics in the development of the assay. The Architect HE4 assay is also approved for use in Europe, as well as in other countries in Asia Pacific and Latin America. ...................& more
No comments:
Post a Comment